GE HealthCare (GEHC) PT Raised to $104 at Stifel
Stifel analyst Rick Wise raised the price target on GE HealthCare (NASDAQ: GEHC) to $104.00 (from $102.00) while maintaining a Buy rating.
The analyst comments "Following the GEHC 4Q24 call, we came away feeling encouraged about the company’s 4Q24 performance and initial 2025 guide. As noted in our first look, GEHC 4Q24 sales were basically in-line with our expectations, while margins and EPS both surpassed our/Consensus estimates. Underpinning the solid quarter, management highlighted strong organic order growth at ~6% Y/Y, the highest book-to-bill ratio (i.e. orders/sales) since GE Healthcare’s January 2023 spin, and a “record” backlog at ~$19.8B. Despite these positive fundamental indicators, GEHC management underscored their goal to take a measured approach in setting 2025 guidance. Initial 2025 EBIT and EPS guidance did capture Consensus estimates…but the full-year 2025 organic sales guidance calls for 2%-3% Y/Y growth i.e. below our/Consensus’ original 3.5%/3.8% Y/Y organic growth estimates. However, GEHC indicated that this measured approach to 2025 guidance reflects their view on both the China-related market dynamics and tariff impacts."